Table 1 Patient demographics and its association with mitotic count and recurrence

From: A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma

Variables

N

%

Mitotic count (mean±s.d.)

P-value

5-year RFP (%)

P-value

All patients

485

100

5.1±6.8

   

Age (years)

   

0.002

 

0.320

 ≤65

176

36

4.5±6.7

 

80

 

 >65

309

64

6.1±6.9

 

84

 

Gender

   

0.355

 

0.001

 Female

306

63

4.8±6.2

 

87

 

 Male

179

37

5.7±7.7

 

73

 

Smoking status

   

<0.001

 

0.088

 Never

72

15

2.1±2.4

 

90

 

 Former/current

413

85

5.7±7.2

 

81

 

Laterality

   

0.274

 

0.570

 Left

205

42

5.0±6.9

 

81

 

 Right

280

58

5.2±6.7

 

83

 

Stage

   

<0.001

 

<0.001

 IA

300

62

4.1±5.6

 

87

 

 IB

185

38

6.8±8.1

 

74

 

Pleural invasion

   

<0.001

 

0.008

 Absence

384

79

4.6±6.2

 

84

 

 Presence

101

21

7.1±8.3

 

75

 

Lymphatic invasion

   

<0.001

 

0.001

 Absence

346

71

4.3±6.0

 

86

 

 Presence

139

29

7.1±8.2

 

74

 

Vascular invasion

   

<0.001

 

<0.001

 Absence

340

70

3.6±5.1

 

86

 

 Presence

145

30

8.7±8.7

 

74

 

Necrosis

   

<0.001

 

<0.001

 Absence

391

81

3.5±5.0

 

87

 

 Presence

94

19

11.9±8.7

 

62

 

Histologic subtype

   

<0.001

 

<0.001

 AIS/MIA

9

2

0.1±0.3

 

100

 

 Lepidic

27

6

1.2±1.4

 

89

 

 Papillary

140

29

3.7±4.9

 

83

 

 Acinar

231

48

4.8±6.5

 

85

 

 Micropapillary

12

3

5.0±3.4

 

64

 

 Solid

66

14

11.6±9.1

 

69

 

Architectural grade

   

<0.001

 

<0.001

 Low

36

7

0.9±1.3

 

92

 

 Intermediate

371

76

4.4±6.0

 

84

 

 High

78

16

10.6±8.8

 

68

 
  1. Abbreviations: AIS, adenocarcinoma in situ; RFP, recurrence-free probability; MIA, minimally invasive adenocarcinoma.
  2. Significant P-values are shown in bold: P-values for mitotic count from Wilcoxon test and for survival from log-rank test.